isopropyl 3-aminocyclohexanecarboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: isopropyl 3-aminocyclohexanecarboxylate
• 英文别名: propan-2-yl 3-aminocyclohexane-1-carboxylate
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: KWLCPDIBEGTZTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  isopropyl 3-aminocyclohexanecarboxylate 在 甲醇 、 immobilized Candida Antarctica B 、 水 、 sodium hydroxide 作用下， 反应 20.17h， 生成 (1S,3R)-3-acetamidocyclohexanecarboxylic acid
  参考文献：
  名称：

  Development of an Enantioselective Novozym 435 Mediated Acetylation for the Preparation of (1S,3R)-3-Acetamidocyclohexane-1-carboxylic Acid

  摘要：

  Starting from a cheap and readily available starting material, a short and enantioselective route to (1S,3R)-3-acetamidocyclohexane-1-carboxylic acid was developed. The key steps were a rhodium catalyzed hydrogenation of 3-aminobenzoic acid and an enantioselective Novozym 435 mediated acetylation of racemic isopropyl 3-aminocyclohexanecarboxylate.

  DOI：

  10.1021/acs.oprd.6b00146
• 作为产物：
  描述：

  3-氨基苯甲酸异丙酯 在 氢气 、 铑 作用下， 以 异丙醇 为溶剂， 以60%的产率得到
  参考文献：
  名称：

  Development of an Enantioselective Novozym 435 Mediated Acetylation for the Preparation of (1S,3R)-3-Acetamidocyclohexane-1-carboxylic Acid

  摘要：

  Starting from a cheap and readily available starting material, a short and enantioselective route to (1S,3R)-3-acetamidocyclohexane-1-carboxylic acid was developed. The key steps were a rhodium catalyzed hydrogenation of 3-aminobenzoic acid and an enantioselective Novozym 435 mediated acetylation of racemic isopropyl 3-aminocyclohexanecarboxylate.

  DOI：

  10.1021/acs.oprd.6b00146

文献信息

• Chemical Compounds
  申请人：AstraZeneca AB

  公开号：US20160376287A1

  公开（公告）日：2016-12-29

  Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

  提供了一系列新颖的吡啶或嘧啶衍生物，可以抑制CDK9，并可能对治疗过度增殖性疾病有用。特别是这些化合物在治疗增殖性疾病方面具有用途，如癌症，包括血液恶性肿瘤，如急性髓细胞白血病，多发性骨髓瘤，慢性淋巴细胞白血病，弥漫性大B细胞淋巴瘤，Burkitt淋巴瘤，滤泡性淋巴瘤以及实体肿瘤，如乳腺癌，肺癌，神经母细胞瘤和结肠癌。
• Using Spinchem Rotating Bed Reactor Technology for Immobilized Enzymatic Reactions: A Case Study
  作者：Subhash Pithani、Staffan Karlsson、Hans Emtenäs、Christopher T. Öberg

  DOI：10.1021/acs.oprd.9b00240

  日期：2019.9.20

  due to mechanical stress, and ease of workup and recovery on scale. Herein, we report on the use of a SpinChem rotating bed reactor (RBR) for the Novozyme 435 mediated kinetic resolution of (cis)-isopropyl 3-aminocyclohexanecarboxylate as an alternative to the traditional reaction using free-flowing immobilized lipases in an ordinary batch reactor. Reusability was studied in addition to other parameters

  固定化酶在医药和大宗化学品生产中的实际和财务上可行的使用要求高度催化活性的酶和有效的底物向活性位的质量转移。固定化酶的大量成本进一步要求延长酶的重复使用量，以降低运营支出。固定化酶的再利用程度取决于参数，例如酶在工艺条件下的长期稳定性，由于机械应力导致的载体完整性和磨损，以及易于大规模生产和回收的参数。在此，我们报告了将SpinChem旋转床反应器（RBR）用于Novozyme 435介导的（顺式）动力学拆分。）3-氨基异丙基环己烷甲酸异丙酯作为在常规间歇反应器中使用自由流动的固定化脂肪酶的传统反应的替代方法。除其他参数外，还研究了可重用性，例如固定化酶的类型，负载，搅拌速度，温度和可扩展性。通过使用SpiChem RBR技术，我们发现固定化酶的回收很容易，同时保留了对映选择性和催化活性。最终的优化工艺成功地以1 kg规模得到了证明，分离产率为39％，对映体纯度为98.8％。
• [EN] POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS<br/>[FR] DÉRIVÉS D'AMIDES POLYCYCLIQUES COMME INHIBITEURS DE LA CDK9
  申请人：ASTRAZENECA AB

  公开号：WO2017001354A1

  公开（公告）日：2017-01-05

  Provided are a series of novel pyridine or pyrimidine derivatives of Formula (I) which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative diseases such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer. A is C(R5) or N; R5 is H, C1-3alkyl, CN or halogen; R2 is optionally substituted 3-7 membered heterocycloalkyl or 3-7 membered cycloalkyl; R4 is (A) or (B) wherein X and Y together with the atoms to which they are attached form an optionally substituted, saturated or partially saturated 5 to 7 membered heterocycloalkyl ring which, in addition to the bridge nitrogen, may contain one or two heteroatoms selected from N, O, and S; J is N or CR11; and R11 is H or C1-3alkyl.

  提供了一系列新型的吡啶或嘧啶衍生物，其化学式为（I），可以抑制CDK9，并可能用于治疗过度增殖性疾病。特别是这些化合物可用于治疗增殖性疾病，如癌症，包括血液恶性肿瘤，如急性髓性白血病，多发性骨髓瘤，慢性淋巴细胞白血病，弥漫性大B细胞淋巴瘤，伯基特淋巴瘤，滤泡性淋巴瘤和实体瘤，如乳腺癌，肺癌，神经母细胞瘤和结肠癌。其中，A是C（R5）或N；R5是H，C1-3烷基，CN或卤素；R2是可选择的取代的3-7成员杂环烷基或3-7成员环烷基；R4是（A）或（B），其中X和Y与它们连接的原子一起形成一个可选择的取代的，饱和或部分饱和的5到7成员杂环烷基环，除了桥氮外，可能包含一个或两个从N，O和S中选择的杂原子；J是N或CR11；R11是H或C1-3烷基。
• Chemical compounds
  申请人：ASTRAZENECA AB

  公开号：US10717746B2

  公开（公告）日：2020-07-21

  Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

  本研究提供了一系列新型吡啶或嘧啶衍生物，它们能抑制 CDK9，可用于治疗增殖过快的疾病。特别是这些化合物可用于治疗增殖性疾病，如癌症，包括血液恶性肿瘤，如急性髓性白血病、多发性骨髓瘤、慢性淋巴细胞白血病、弥漫性大 B 细胞淋巴瘤、伯基特淋巴瘤、滤泡性淋巴瘤和实体瘤，如乳腺癌、肺癌、神经母细胞瘤和结肠癌。
• Pyridine and pyrimidine derivatives
  申请人：ASTRAZENECA AB

  公开号：US11352369B2

  公开（公告）日：2022-06-07

  Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

  本研究提供了一系列新型吡啶或嘧啶衍生物，它们能抑制 CDK9，可用于治疗增殖过快的疾病。特别是这些化合物可用于治疗增殖性疾病，如癌症，包括血液恶性肿瘤，如急性髓性白血病、多发性骨髓瘤、慢性淋巴细胞白血病、弥漫性大 B 细胞淋巴瘤、伯基特淋巴瘤、滤泡性淋巴瘤和实体瘤，如乳腺癌、肺癌、神经母细胞瘤和结肠癌。